Differential tumor-targeting abilities of three single-domain antibody formats.
about
Crystal Structure of a Human Single Domain Antibody Dimer Formed through VH-VH Non-Covalent InteractionsA nanobody targeting carcinoembryonic antigen as a promising molecular probe for non-small cell lung cancerSynthesis of BODIPY-Peptide Conjugates for Fluorescence Labeling of EGFR Overexpressing Cells.Molecular imaging of breast tumors using a near-infrared fluorescently labeled clusterin binding peptide.Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours.Antibody phage display libraries: contributions to oncology.Single-domain antibodies and their utility.Preclinical evaluation of Mab CC188 for ovarian cancer imagingA Rational Engineering Strategy for Designing Protein A-Binding Camelid Single-Domain AntibodiesPreparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3).Use of the single cell gel electrophoresis (comet assay) for comparing apoptotic effect of conventional antibodies versus nanobodiesTumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli.Recent advances in technology supporting biopharmaceutical production from mammalian cells.Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target.Biology of telomeres: lessons from budding yeast.Nanobody-based cancer therapy of solid tumors.A semi-empirical glycosylation model of a camelid monoclonal antibody under hypothermia cell culture conditions.Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent.Low glucose depletes glycan precursors, reduces site occupancy and galactosylation of a monoclonal antibody in CHO cell culture.A simultaneous assessment metric for MAb quantity and glycan quality.Monitoring the dielectric response of single cells following mitochondrial adenosine triphosphate synthase inhibition by oligomycin using a dielectrophoretic cytometer.Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.Single-Domain Antibodies As Therapeutics against Human Viral Diseases.The changing dielectric properties of CHO cells can be used to determine early apoptotic events in a bioprocess.Development of a bispecific antibody tetramerized through hetero-associating peptides.An efficient protocol towards site-specifically clickable nanobodies in high yield: cytoplasmic expression in Escherichia coli combined with intein-mediated protein ligation.(99m) Tc-labeled tetramer and pentamer of single-domain antibody for targeting epidermal growth factor receptor in xenografted tumors.Purification of chimeric heavy chain monoclonal antibody EG2-hFc using hydrophobic interaction membrane chromatography: an alternative to protein-A affinity chromatography.
P2860
Q27676789-866BA43F-2E2C-43BB-9144-09197BD44657Q33827932-5055D5BF-C64E-4E82-B000-331F4EB4437EQ33898658-91F7373D-D87B-4408-AF00-9F89FFAF943CQ34084282-61C11CAC-B42C-4CFA-A9B5-3F61FDD612F6Q34112887-2E87A3E7-7331-4472-82E5-4538C98918B5Q34323991-1B180F29-1B16-4E6F-8D91-A50546EF61F8Q35089545-3802958C-4BB5-42D9-95DB-38030F824013Q35919110-1E179DAE-04B1-49AE-A8A3-C13E0E37A058Q36134100-772EE0C4-4BA7-4048-818E-BED033E21BF0Q36213059-C9E5EE03-8AD9-47C2-AF84-1CF2DCB17601Q37098867-70616442-398D-4570-AB86-B82444FF0E1AQ37224751-1093C145-D159-422B-9D92-6728D986F4DBQ37283860-5BA08D72-5F02-4FE9-A707-991FE9FFEE38Q38050998-9420F30C-2FCA-4A2D-9025-64C79E4E3F7FQ38071119-C7CA5A54-D37A-49EA-BC26-EA897F0AD35AQ38106992-9593B11C-46DD-4CBD-8365-98F2E2CF0011Q38206208-668A1CEA-A646-4513-B78A-6C6A5317512CQ38322471-D7A8DD6A-C7CF-45B0-A974-625E3009CD34Q38712568-14CA0C55-F204-4C02-AC65-C1F5297A4D99Q38845254-DBDA592D-FA33-4957-A8D3-37BA3F6DC1CFQ39433833-38E0D057-90D7-4DC3-8146-55C1E953DB24Q39577966-8E7828E3-236F-4CEB-87CF-BDD9F4600B38Q40853167-31BEFCA1-5A27-4E72-A16E-2FCF99DA144FQ41639511-100B4E97-AA9D-43A0-91FF-5424C70EF2D1Q42551550-27596527-B071-4768-AAD7-107BABB36CA7Q47121798-CB34BFB5-44BD-4B51-887A-2871561489CFQ47554821-E6B0F74B-DC9A-457A-8788-36DA20D247C9Q50231756-C19A3466-5B20-4CE8-839F-607FA5579A28Q51784482-664C3013-4C5E-411C-8E7E-21826F597959Q51820924-CB552477-F3DC-4385-9FD4-472856919F77Q52983329-A12187A3-2A2C-4F48-82EE-DC7921F0BC54Q53635304-B2E2FD96-CAE7-4AB7-A188-8A74A636B22E
P2860
Differential tumor-targeting abilities of three single-domain antibody formats.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Differential tumor-targeting abilities of three single-domain antibody formats.
@ast
Differential tumor-targeting abilities of three single-domain antibody formats.
@en
type
label
Differential tumor-targeting abilities of three single-domain antibody formats.
@ast
Differential tumor-targeting abilities of three single-domain antibody formats.
@en
prefLabel
Differential tumor-targeting abilities of three single-domain antibody formats.
@ast
Differential tumor-targeting abilities of three single-domain antibody formats.
@en
P2093
P1433
P1476
Differential tumor-targeting abilities of three single-domain antibody formats.
@en
P2093
Andrea Bell
Jason Baardsnes
Jianbing Zhang
Maria L Jaramillo
Maureen O'Connor-McCourt
Mehdi Arbabi-Ghahroudi
Roger Mackenzie
Shenghua Li
Tingtung A Chang
Toya N Baral
P356
10.1016/J.CANLET.2009.08.003
P407
P577
2009-08-28T00:00:00Z